Absolutely. The phase 2 showed that exenatide reduced ICP. PT320 is just a weekly formulation.
By the same logic, if we had proceeded to making the daily formulation of presendin, would we have re-run the phase 2 trial? We wouldnt have, but we would have gone straight to Phase 3.
Ann: Notice of Investor Call and Presentation, page-105
Add IXC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.463M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 74259 | 8.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.8¢ | 5755 | 1 |
View Market Depth
| Last trade - 10.04am 16/10/2024 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable